ClinConnect ClinConnect Logo
Search / Trial NCT01942369

A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

Launched by IPSEN · Sep 10, 2013

Trial Information

Current as of July 21, 2025

Completed

Keywords

Endometriosis

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Patients diagnosed with DIE and having received surgery treatment within one month before inclusion
  • Premenopausal women aged \>=18 years old.
  • Written ICF has been obtained prior to any study-related procedures
  • Patient for whom the treating physician already made the decision to treat by Diphereline.
  • Patient should be mentally and physically able to express her symptom complaints and answer questions.
  • Exclusion Criteria:
  • Pregnancy or lactation.
  • Patients currently on treatment or who have been on therapy with a GnRHa in the last 6 months.
  • Premenopausal women who may reach menopause within the 3 years post randomisation.
  • Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg
  • Treatment with another research drug over the last 3 months before the study
  • Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.

About Ipsen

Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.

Locations

Beijing, , China

Beijing, , China

Beijing, , China

Beijing, , China

Chongqing, , China

Chongqing, , China

Hangzhou, , China

Hefei, , China

Nanchang, , China

Nanjing, , China

Shanghai, , China

Shanghai, , China

Shanghai, , China

Shenzhen, , China

Taiyuan, , China

Wuhan, , China

Wuhan, , China

Zhengzhou, , China

Patients applied

0 patients applied

Trial Officials

Ipsen Medical Director

Study Director

Ipsen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials